Proactive Investors - Run By Investors For Investors

Bristol-Myers falls after Citi analyst says Pfizer not interested in buying the drugmaker

New York pharma giant is also working with Harvard researchers to develop fibrotic disease treatments
Pills spilling out from a vial
The drugmaker will hold an investor event to discuss its new lung-cancer study

Bristol-Myers Squibb Co (NYSE:BMY) shares were down Thursday while Pfizer Inc. (NYSE:PFE) rose after an analyst for Citi Investment Research said a deal between the two drugmakers isn't likely to happen.

Bristol-Myers lost 2% to US$58.96, while Pfizer rose 1.7% to US$36.38 in midday trade.

Citi analyst Andrew Baum said he met with Pfizer CEO Ian Read and he had "no interest" in Bristol-Myers or other major deals right now.

"In our meeting yesterday with Pfizer’s CEO, COO and CSO, Pfizer made clear that they had no interest in BMY in the absence of transformational data or de-rating of the shares,” Baum was quoted as saying in a Citi research report shared with Streetinsider.com.

In February, Baum had laid out a scenario where Pfizer may look to buy its rival despite its large market cap.

The Citi analyst cut his price target to US$70 from US$78 after he removed a US$8 a share M&A risk premium from his target price.

"We view our newly lowered target price as conservative given the absence of contribution from CHECKMATE-9LA in 1st line non-small cell lung cancer,” Baum wrote in the report.

Investors will get a look at results next week from Bristol-Myers’s Phase 3 study of Opdivo and Yervoy in patients newly diagnosed with advanced lung cancer with high tumor mutational burden.

The New York-based drugmaker will hold an investor event to discuss the lung-cancer data on Monday at 5 p.m. CT.

Teaming up with Harvard researchers

Separately, Bristol-Myers announced on Thursday that it was working on research with the Harvard Fibrosis Network of the Harvard Stem Cell Institute to develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart.

“Bristol-Myers Squibb strives to develop transformational therapies that arrest or reverse the progression of fibrosis and restore organ function,” said Carl Decicco, head of discovery at Bristol-Myers Squibb. “We believe this collaboration will advance fibrosis research…and the development of new therapies for patients with these debilitating conditions.”

View full BMY profile View Profile

Bristol-Myers Squibb Co Timeline

Related Articles

LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use